Neuronetics (STIM)
Sells NeuroStar TMS systems and operates Greenbrook mental-health treatment centers.
Something off on this page? Send us feedback.
Sells NeuroStar TMS systems, recurring treatment sessions, and direct clinic services for depression-related care. The Greenbrook acquisition shifted the model into medical device and clinic services segments, with operations concentrated in the United States.
Sells and supports the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation platform used for major depressive disorder and related mental-health indications. Revenue comes from system placements, recurring treatment sessions, service and support, and Greenbrook clinic services.
Operates mostly in the United States after the Greenbrook acquisition, which added company-operated treatment centers and shifted the business into a vertically integrated model. Medical device and clinic services are now the reported operating segments.
Execution depends on provider adoption, clinic utilization, FDA-cleared indications, and third-party insurance coverage for treatments using its products and services.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 11, 2026 | B. Riley | Initiate | Rating: — | |
| Jul 20, 2026 | BTIG | Initiate | Rating: —Target: — | Target: $5 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $19.4M · Total debt $86.5M · Total assets $131.5M · Shareholders' equity $17.9M
- Revenue
- $41.6M
- Operating income
- −$1.5M
- Net income
- −$3.4M
No dividends on record.
| Institutions | 53.48% | 37.22M shares | |
|---|---|---|---|
| 92 holders · as of Jun 30, 2026 | |||
| Insiders | 24.43% | 17.00M shares | |
| 14 holders · as of Aug 24, 2026 | |||
| Other | 22.09% | 15.37M shares | |
| remainder | |||
69.59M company shares as of Sep 19, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (76.20M in the company's Sep 22, 2026 report, 69.59M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Madryn Asset Management, LPInstitution | 26.64% | 18.54M | as of Jun 30, 2026 |
Jorey ChernettInsider10 percent owner | 15.24% | 10.60M | filed Aug 24, 2026 |
Parian Ultreia LPInstitution | 6.96% | 4.84M | filed Mar 17, 2026 |
Point72 Asset Management, L.P.Institution | 5.49% | 3.82M | filed Aug 14, 2026 |
UBS Group AGInstitution | 3.28% | 2.28M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | Jorey Chernett | 10 percent owner | −100 | $5.00 |
| Aug 14, 2026 | Jorey Chernett | 10 percent owner | +14,000 | $3.16 |
| Jul 14, 2026 | Jorey Chernett | 10 percent owner | +35,000 | $1.78 |
| Mar 19, 2026 | Steven Pfanstiel | officer: Former EVP, CFO and Treasurer | −25,000 | $1.34 |
| May 19, 2026 | Jorey Chernett | 10 percent owner | +100,000 | $1.17 |
- BrainsWay (ADR)
Direct Deep TMS rival for depression and OCD clinics
- LifeStance Health
Outpatient mental health network with TMS service overlap
- Johnson & Johnson
SPRAVATO owner in treatment-resistant depression
- Acadia Healthcare
Behavioral health facility operator competing for patient flow
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Neuronetics | $2.94 | +2.98% | $198.3M | — | — | 1.3 | +9.1% |
| BrainsWay (ADR) | $13.67 | +0.70% | $532.3M | 30.8 | 31.1 | 8.7 | +35.4% |
| LifeStance Health | $12.76 | +0.67% | $4.91B | 97.7 | 58.5 | 3.1 | +26.1% |
| Johnson & Johnson | $269.57 | +0.04% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Acadia Healthcare | $29.25 | +3.10% | $2.64B | — | 17.6 | 0.8 | −0.4% |
| Median | 31.2 | 26.9 | 4.9 | +16.3% |